Osiris Therapeutics Company Profile (NASDAQ:OSIR)

About Osiris Therapeutics

Osiris Therapeutics logoOsiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body's natural healing. The Company's products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company's BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: OSIR
  • CUSIP: 68827R10
Key Metrics:
  • Previous Close: $5.66
  • 50 Day Moving Average: $5.44
  • 200 Day Moving Average: $5.20
  • 52-Week Range: $3.55 - $7.87
  • Trailing P/E Ratio: 134.76
  • Foreward P/E Ratio: 80.86
  • P/E Growth: 0.00
  • Market Cap: $195.00M
  • Outstanding Shares: 34,452,000
  • Beta: 0.79
Additional Links:
Companies Related to Osiris Therapeutics:

Analyst Ratings

Consensus Ratings for Osiris Therapeutics (NASDAQ:OSIR) (?)
Ratings Breakdown: 1 Sell Rating
Consensus Rating:Sell (Score: 1.00)
Consensus Price Target: $4.00 (29.33% downside)

Analysts' Ratings History for Osiris Therapeutics (NASDAQ:OSIR)
Show:
DateFirmActionRatingPrice TargetDetails
3/16/2016Brean CapitalReiterated RatingSell$4.00View Rating Details
2/2/2016Piper Jaffray CompaniesReiterated RatingBuyView Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Osiris Therapeutics (NASDAQ:OSIR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/7/2016        
11/6/2015Q315$0.06($0.02)$25.40 million$24.30 millionViewN/AView Earnings Details
8/5/2015Q215$0.06$0.03$23.60 million$23.70 millionViewN/AView Earnings Details
5/8/2015Q115$0.04$18.40 million$21.00 millionViewN/AView Earnings Details
3/5/2015Q414$0.05$0.03$18.53 million$19.50 millionViewN/AView Earnings Details
11/7/2014Q314($0.01)$0.02$14.80 million$17.20 millionViewN/AView Earnings Details
8/7/2014Q214$0.16($0.04)$11.00 million$13.30 millionViewN/AView Earnings Details
5/12/2014($0.08)($0.02)ViewN/AView Earnings Details
3/5/2014Q413$0.65$0.11$7.50 million$8.10 millionViewN/AView Earnings Details
11/1/2013Q313($0.10)($0.05)$6.70 million$6.88 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.09)($0.11)$4.35 million$5.29 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.09)($0.08)$3.53 million$4.06 millionViewN/AView Earnings Details
11/5/2012Q312($0.14)($0.09)$1.89 million$2.15 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Osiris Therapeutics (NASDAQ:OSIR)
Current Year EPS Consensus Estimate: $0.14 EPS
Next Year EPS Consensus Estimate: $0.07 EPS

Dividends

Dividend History for Osiris Therapeutics (NASDAQ:OSIR)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/17/2015special$0.209/14/20159/16/20159/30/2015
9/17/2015special$0.2010/14/201510/16/201510/30/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Osiris Therapeutics (NASDAQ:OSIR)
Insider Ownership Percentage: 44.60%
Institutional Ownership Percentage: 19.88%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/27/2014Matthew Paul NeumayerInsiderSell3,750$16.10$60,375.00View SEC Filing  
5/21/2014Philip Jacoby, Jr.CFOSell15,947$15.43$246,062.21View SEC Filing  
3/14/2014Michelle Leroux WilliamsInsiderSell61,934$14.09$872,650.06View SEC Filing  
11/25/2013Philip Jacoby, Jr.CFOSell18,372$15.99$293,768.28View SEC Filing  
11/15/2013Michelle Leroux WilliamsInsiderSell24,500$15.50$379,750.00View SEC Filing  
8/20/2013Matthew Paul NeumayerInsiderSell11,375$19.75$224,656.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Osiris Therapeutics (NASDAQ:OSIR)
DateHeadline
News IconStock Volatility Review for Osiris Therapeutics, Inc. (NASDAQ:OSIR) - BVN (NASDAQ:OSIR)
bvnewsjournal.com - February 23 at 7:09 PM
News IconRegenerative medicine market worth 38.70 billion USD by 2021 examined in new market research report (NASDAQ:OSIR)
www.whatech.com - February 23 at 12:10 AM
openpr.com logoOrthobiologics Market 2015-2022, Industry Analysis, Size, Share, Trends, Segment & Forecast scrutinized in New Research (NASDAQ:OSIR)
www.openpr.com - February 22 at 9:09 AM
News IconBrokers Add To Their Ratings On Osiris Therapeutics, Inc. (OSIR) - NewsDen (NASDAQ:OSIR)
newsden.net - February 16 at 6:40 PM
News IconIndicators in Focus on Osiris Therapeutics, Inc. (NASDAQ:OSIR) - Searcy News (NASDAQ:OSIR)
searcysentinel.com - February 16 at 6:40 PM
prnewswire.com logoRegenerative Medicine Market Growing at a CAGR of 23.6 % During 2016 to 2021 (NASDAQ:OSIR)
www.prnewswire.com - February 16 at 6:40 PM
News IconBronchitis Treatment Global Market Trend, Research Approach, Data Analysis and Forecast to 2022 (NASDAQ:OSIR)
www.emailwire.com - February 16 at 6:40 PM
News IconOsiris Appoints Uwe Sommer and Thomas Knapp to its Board of Directors - OrthoSpineNews (NASDAQ:OSIR)
www.orthospinenews.com - February 14 at 10:52 PM
einnews.com logoPrince's Warner Bros. catalog goes to all streaming services (NASDAQ:OSIR)
www.einnews.com - February 13 at 9:33 AM
marketexclusive.com logoOSIRIS THERAPEUTICS,INC. (NASDAQ:OSIR) Files An 8-K Departure of Directors or Certain Officers; Election of ... - Market Exclusive (NASDAQ:OSIR)
marketexclusive.com - February 12 at 11:56 PM
News IconOsiris Appoints Uwe Sommer and Thomas Knapp to its Board of Directors - ForexTV.com (NASDAQ:OSIR)
forextv.com - February 11 at 1:04 AM
News IconInvestor Radar: Focusing in on Shares of Osiris Therapeutics, Inc ... - Benton Bulletin (NASDAQ:OSIR)
bentonbulletin.com - February 11 at 1:04 AM
prnewswire.com logoRegenerative Medicine Market Worth 38.70 Billion USD by 2021 (NASDAQ:OSIR)
www.prnewswire.com - February 10 at 8:02 PM
finance.yahoo.com logoOsiris Appoints Uwe Sommer and Thomas Knapp to its Board of Directors (NASDAQ:OSIR)
finance.yahoo.com - February 10 at 8:02 PM
biz.yahoo.com logoOSIRIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh (NASDAQ:OSIR)
biz.yahoo.com - February 10 at 8:02 PM
sbwire.com logoKnee Cartilage Repair Market Is Estimated to Reach a Market Value of US $2.7 Bn in 2023 (NASDAQ:OSIR)
www.sbwire.com - February 8 at 8:03 PM
biz.yahoo.com logoOSIRIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:OSIR)
biz.yahoo.com - February 8 at 8:03 PM
News IconSlone Partners Lands Chief Medical Officer for Clinical Genomics (NASDAQ:OSIR)
huntscanlon.com - February 6 at 7:09 PM
News IconMA Levels in Review for Osiris Therapeutics Inc. (OSIR) - Sherwood Daily (NASDAQ:OSIR)
sherwooddaily.com - February 2 at 7:59 PM
News IconStock Dragging Lower Heading Into The Open: Osiris Therapeutics ... - Aiken Advocate (NASDAQ:OSIR)
aikenadvocate.com - February 2 at 1:17 AM
News IconEquity Focus: Indicator Check on Shares of Osiris Therapeutics Inc. (OSIR) - Sherwood Daily (NASDAQ:OSIR)
sherwooddaily.com - January 31 at 5:49 AM
nasdaq.com logoMid-Afternoon Market Update: Celestica Rises On Earnings Beat; KEYW Shares Slide - Nasdaq (NASDAQ:OSIR)
www.nasdaq.com - January 30 at 12:34 AM
News IconEnlivened Volatility Spotted in Shares of Osiris Therapeutics, Inc. (NASDAQ:OSIR) - Wall Street Beacon (NASDAQ:OSIR)
wsbeacon.com - January 25 at 11:22 PM
News IconTrump Sworn In as S&P Declined, How Did this Stock Perform This Week: Osiris Therapeutics, Inc. (NASDAQ:OSIR) - Aiken Advocate (NASDAQ:OSIR)
aikenadvocate.com - January 22 at 6:52 PM
News IconCCI Level Check for Osiris Therapeutics Inc. (OSIR) - Sherwood Daily (NASDAQ:OSIR)
sherwooddaily.com - January 22 at 6:52 PM
News IconLooking at Moving Averages for Osiris Therapeutics Inc. (OSIR) - Rives Journal (NASDAQ:OSIR)
rivesjournal.com - January 21 at 12:58 AM
News IconShould You Buy Or Sell Osiris Therapeutics, Inc. (OSIR) On Analyst Concensus? - NewsDen (NASDAQ:OSIR)
newsden.net - January 20 at 7:55 PM
globenewswire.com logoOsiris Therapeutics announced a Comparative Effectiveness Study on the Use of Two Human Placental Membranes in ... - GlobeNewswire (press release) (NASDAQ:OSIR)
globenewswire.com - January 20 at 4:45 AM
tmcnet.com logoOsiris Therapeutics announced a Comparative Effectiveness Study on... (NASDAQ:OSIR)
www.tmcnet.com - January 19 at 11:44 PM
globenewswire.com logoOsiris Therapeutics announced a Comparative Effectiveness Study on the ... (NASDAQ:OSIR)
globenewswire.com - January 19 at 11:44 PM
finance.yahoo.com logoOsiris Therapeutics announced a Comparative Effectiveness Study on the Use of Two Human Placental Membranes in Wound Management is Available Electronically in a Peer-Reviewed Journal (NASDAQ:OSIR)
finance.yahoo.com - January 19 at 11:44 PM
News IconCalifornia’s stem cell agency will run out of money in three years. Should voters OK spending more? (NASDAQ:OSIR)
www.sacbee.com - January 17 at 11:14 AM
finance.yahoo.com logoOsiris Therapeutics Announces Scientific Manuscript Reporting Antimicrobial Properties of Cryopreserved Viable Amnion is Available Electronically in Peer-Reviewed Journal (NASDAQ:OSIR)
finance.yahoo.com - January 13 at 11:58 PM
finance.yahoo.com logo5:04 pm Osiris Therapeutics announced that new peer-reviewed manuscript 'Human cryopreserved viable amniotic membrane inhibits the growth of bacteria associated with chronic wounds' was published in Journal of Diabetic Foot Complications (NASDAQ:OSIR)
finance.yahoo.com - January 13 at 11:58 PM
News IconMAHONING COUNTY COURTS (NASDAQ:OSIR)
www.vindy.com - January 12 at 5:45 AM
News IconDiscover the Global Cartilage Repair Or Cartilage Regeneration Market Research Report 2016 (NASDAQ:OSIR)
empowerednews.net - January 11 at 7:43 PM
sbwire.com logoCartilage Repair/ Cartilage Regeneration Market - Forecast to 2021 - New Market Study Published (NASDAQ:OSIR)
www.sbwire.com - January 9 at 7:46 PM
News IconCoulter Partners Taps Chief Medical Officer for Albumedix (NASDAQ:OSIR)
huntscanlon.com - January 5 at 12:52 AM
News IconNew Study: Cartilage Repair/ Cartilage Regeneration Market - Forecast to 2021 (NASDAQ:OSIR)
reports.pr-inside.com - December 27 at 6:54 PM
News IconCompany Shares in Review: Osiris Therapeutics, Inc. (NASDAQ:OSIR) - OIB News (NASDAQ:OSIR)
oibnews.com - December 21 at 7:55 PM
News IconADX, MA, and RSI in Focus for Osiris Therapeutics Inc. (OSIR) - Yankee Analysts (NASDAQ:OSIR)
yankeeanalysts.com - December 21 at 7:55 PM
News IconShares in Focus: Osiris Therapeutics, Inc. (NASDAQ:OSIR) - OIB News (NASDAQ:OSIR)
oibnews.com - December 20 at 1:30 PM
insidermonkey.com logoIs Osiris Therapeutics, Inc. (OSIR) A Good Stock To Buy? - Insider Monkey (blog) (NASDAQ:OSIR)
www.insidermonkey.com - December 20 at 1:30 PM
News IconWatching the Charts on Osiris Therapeutics Inc. (OSIR) - Yankee Analysts (NASDAQ:OSIR)
yankeeanalysts.com - December 20 at 1:30 PM
News IconOsiris Therapeutics, Inc. (NASDAQ:OSIR) reported Beta of 0.74 - The Newburgh Press (NASDAQ:OSIR)
newburghpress.com - December 20 at 1:30 PM
News IconAverage Directional Index Review for Osiris Therapeutics Inc. (OSIR) - Yankee Analysts (NASDAQ:OSIR)
yankeeanalysts.com - December 17 at 7:34 PM
News IconCompany Stock Watch: Osiris Therapeutics, Inc. (NASDAQ:OSIR) - Business Daily Leader (NASDAQ:OSIR)
businessdailyleader.com - December 17 at 7:34 PM
einnews.com logoGlobal Cartilage Repair/Cartilage Regeneration Market Report 2016-2021: Market is Projected to Reach USD 779.8 Million by 2021 (NASDAQ:OSIR)
www.einnews.com - December 16 at 7:49 PM
News IconInvestor Watch: Narrowing in on Osiris Therapeutics, Inc. (NASDAQ:OSIR) - Liberty News (NASDAQ:OSIR)
libertynewsrecord.com - December 15 at 6:04 AM
News IconInvestor Focus on Technical Levels for Osiris Therapeutics Inc. (OSIR) - Yankee Analysts (NASDAQ:OSIR)
yankeeanalysts.com - December 15 at 6:04 AM

Social

What is Osiris Therapeutics' stock symbol?

Osiris Therapeutics trades on the NASDAQ under the ticker symbol "OSIR."

Where is Osiris Therapeutics' stock going? Where will Osiris Therapeutics' stock price be in 2017?

1 analysts have issued 1-year price targets for Osiris Therapeutics' shares. Their predictions range from $4.00 to $4.00. On average, they expect Osiris Therapeutics' stock price to reach $4.00 in the next twelve months.

When will Osiris Therapeutics announce their earnings?

Osiris Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, April, 7th 2016.

What are analysts saying about Osiris Therapeutics stock?

Here are some recent quotes from research analysts about Osiris Therapeutics stock:

  • According to Zacks Investment Research, "Osiris’ third quarter loss was wider-than-expected. The company also said that certain factors impacted third quarter revenues. Although we are encouraged by Osiris' efforts to grow the Biosurgery segment, dependence on a single segment for growth is concerning. Moreover, Osiris is evaluating Grafix for additional indications and disappointing data would have an adverse impact on the shares. Meanwhile, we are positive on Osiris’ deals with Arthrex and Stryker for Cartiform and BIO4, respectively. We are also positive on the company’s sale of its ceMSC business which has not only brought in cash for Osiris in the form of an upfront payment but will also bring in royalties. Expanded sales force, improving Medicare and private reimbursement coverage should drive revenues." (4/11/2016)

  • Brean Capital analysts commented, "Last night after the close, OSIR issued an 8-K indicating that it will not be able to file its 10- K on time, nor within the 15 day extension period, putting the stock at risk for de-listing with NASDAQ. They also indicated all of 2014 through 3Q15 should not be relied upon and will require restatements—not very surprising since 2014 though 2Q15 were already deemed unreliable due to revenue recondition issues, though up until yesterday 3Q15 was conspicuously deemed reliable. Finally, the company was subpoenaed by the SEC as part of an investigation into accounting practices, and the related accounting issues have precipitated 2 additional lawsuits. While we had warned of the likelihood of such delays in filings (hence our Sell rating), we remain cautious on the company’s ability to remedy these issues and re-issue reliable financial statements. This will likely be a protracted process, creating at least several quarters of uncertainty. In such situations, stocks trade at 1x sales at best (implying $4), but this may prove optimistic given the uncertainty over the 2016 revenue outlook. We are projecting 13% revenue growth, which is now in doubt due to management changes (resignations of the CEO and COO and its related disruption), unreliability of numbers, and some revenues from residual Ovation sales ($7.6 million as of 3Q) that will not re-occur in 2016." (3/16/2016)

Who owns Osiris Therapeutics stock?

Osiris Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.40%), State Street Corp (0.84%), FMR LLC (0.44%), GSA Capital Partners LLP (0.14%), State Board of Administration of Florida Retirement System (0.07%) and Horizon Kinetics LLC (0.06%).

Who sold Osiris Therapeutics stock? Who is selling Osiris Therapeutics stock?

Osiris Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC.

Who bought Osiris Therapeutics stock? Who is buying Osiris Therapeutics stock?

Osiris Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, GSA Capital Partners LLP and State Street Corp.

How do I buy Osiris Therapeutics stock?

Shares of Osiris Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Osiris Therapeutics stock cost?

One share of Osiris Therapeutics stock can currently be purchased for approximately $5.66.

Osiris Therapeutics (NASDAQ:OSIR) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Osiris Therapeutics (NASDAQ:OSIR)

Earnings History Chart

Earnings by Quarter for Osiris Therapeutics (NASDAQ:OSIR)

Dividend History Chart

Dividend Payments by Quarter for Osiris Therapeutics (NASDAQ:OSIR)

Last Updated on 2/25/2017 by MarketBeat.com Staff